Gapping up
In reaction to strong earnings/guidance:
- DOYU +12.3%, HIBB +9.4%, AZO +3.6%, AMWD +2.4%, NPTN +2.4% (reaffirms second quarter 2020 guidance following recent U.S. Department of Commerce announcements) BAH +2.2%
Select ETFs showing strength:
- IWM +2.9%, XLF +2.6%, XLE +2.5%, SMH +2.3%, DIA +2%, XLK +1.9%, SPY +1.8%, QQQ +1.6%, .
Other news:
- EVFM +38.5% (announces that the FDA has approved Phexxi, a vaginal gel for the prevention of pregnancy) ARGX +29.9% (reports positive topline results from Phase 3 ADAPT trial of Efgartigimod)
- NVAX +19.7% (initiates Phase 1/2 clinical trial of COVID-19 Vaccine)
- CERC +13.4% (Cerecor and Myriad (MYGN) announce that levels of novel cytokine, LIGHT, were highly correlated with disease severity and mortality in a COVID-19 acute respiratory distress syndrome biomarker study)
- ZEAL +12.9% (announces FDA acceptance of NDA for dasiglucagon HypoPal Rescue Pen as treatment for severe hypoglycemia)
- ZYNE +9.6% (announces presentation of phase 2 BELIEVE safety, efficacy and quality of life data in developmental and epileptic encephalopathies)
- RMTI +8% (files New Drug Submission with Health Canada for Triferic AVNU)
- MESO +7.6% (reports clinical outcomes using RYONCIL)
- TAK +4.6% (FDA approval of ALUNBRIG)
- CODX +4.5% (COVID-19 test successfully used to identify coronavirus in cancer tissue)
- KAR +3.8% (announces $550 million strategic investment led by funds advised by Apax Partners)
- MRK +3.2% (announces multiple scientific efforts to combat COVID-19; to collaborate with IAVI to develop vaccine against COVID-19)
- TEVA +2% (presents new data for AJOVY)
- MANU +1.7% (currently anticipates a return to play during the month of June 2020)
- TSN +1.3% (announces results of facility-wide testing for COVID-19 at Virginia poultry facility)
Analyst comments:
- CREE +6.1% (upgraded to Mkt Outperform from Mkt Perform at JMP Securities)
- ACLS +4.3% (upgraded to Buy from Neutral at B. Riley FBR)
- IRBT +4.3% (upgraded to Neutral from Underweight at JP Morgan)
- ARR +4.2% (upgraded to Neutral from Underperform at Credit Suisse)
- ROK +2.8% (upgraded to Buy from Neutral at BofA/Merrill)
- JBHT +2.1% (upgraded to Outperform from Neutral at Robert W. Baird)
- HPE +1.3% (upgraded to Neutral from Underweight at JP Morgan)